We are live on ! Find out more
OCUL icon

Ocular Therapeutix
OCUL

37 hedge funds and large institutions have $176M invested in Ocular Therapeutix in 2014 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 16 increasing their positions, 8 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 8

70% more capital invested

Capital invested by funds: $104M → $176M (+$72.6M)

67% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 6

9% more funds holding

Funds holding: 34 → 37 (+3)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
37
Holders Change
+3
Holders Change %
+8.82%
% of All Funds
0.99%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
10
Increased
16
Reduced
8
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$4.68M
2
Principal Financial Group
Principal Financial Group
Iowa
+$2.09M
3
RIM
RS Investment Management
California
+$1.93M
4
LCP
Lamond Capital Partners
California
+$1.25M
5
Northern Trust
Northern Trust
Illinois
+$793K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$3.33M
2
PCM
Pentwater Capital Management
Florida
-$1.51M
3
Morgan Stanley
Morgan Stanley
New York
-$855K
4
BIT
BlackRock Institutional Trust
California
-$587K
5
Millennium Management
Millennium Management
New York
-$323K
Name Holding Trade Value Shares
Change 		Change in
Stake
LPL Financial
26
LPL Financial
California
$212K +$151K +9,000 New
TA
27
Teachers Advisors
New York
$195K +$49.6K +2,948 +55%
NFA
28
Nationwide Fund Advisors
Ohio
$107K +$48.9K +2,907 +178%
AIG
29
American International Group
New York
$85K +$60.8K +3,615 New
Barclays
30
Barclays
United Kingdom
$61K +$44.2K +2,627 New
BA
31
BlackRock Advisors
Delaware
$50K -$16.3K -970 -31%
Royal Bank of Canada
32
Royal Bank of Canada
Ontario, Canada
$17K -$49K -2,911 -80%
UBS Group
33
UBS Group
Switzerland
$13K +$9.45K +562 New
TDC
34
Thompson Davis & Co
Virginia
$9K +$2.1K +125 +50%
Wells Fargo
35
Wells Fargo
California
$6K +$4.49K +267 New
SM
36
Sabby Management
Florida
$2.33K -$3.33M -198,156 -67%
Manulife (Manufacturers Life Insurance)
37
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$38 +$27K +1,607 New
Millennium Management
38
Millennium Management
New York
– -$323K -21,559 Closed
D.E. Shaw & Co
39
D.E. Shaw & Co
New York
– -$205K -13,684 Closed
BG
40
BlackRock Group
United Kingdom
– -$82K -5,487 Closed
SO
41
STRS Ohio
Ohio
– -$30K -2,000 Closed
NFG
42
Next Financial Group
Texas
– -$10K -700 Closed
BJ
43
BlackRock Japan
Japan
– -$5K -348 Closed
1
2

OCUL Hedge Fund Activity: Q4 2014 in Review

37 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q4 2014, worth a combined $176M — up 70% from $104M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new OCUL positions and 6 closed out — a net gain of 4 holders — while 16 added to existing stakes and 8 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $4.68M. The largest seller was Sabby Management, cutting an estimated $3.33M.

  • 37 institutional investors held Ocular Therapeutix (OCUL) as of Q4 2014, up from 34 in Q3 2014.
  • Funds reported $176M of Ocular Therapeutix stock for Q4 2014, up 70% quarter-over-quarter.
  • 10 funds opened new Ocular Therapeutix positions in Q4 2014 and 6 closed out, a net change of +4 holders.
  • The largest Ocular Therapeutix buyer in Q4 2014 was Fidelity Investments, an estimated $4.68M added.
  • The largest Ocular Therapeutix seller in Q4 2014 was Sabby Management, an estimated $3.33M sold.

Based on aggregated 13F filings for Q4 2014.